Cellular Origins appoints Geoff Hodge to its Board as Non-Executive Director

– UK, Royston –  Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, announced the appointment of Geoff Hodge to its Board as Non-Executive Director.

About Geoffrey Hodge

Geoff Hodge was most recently CEO of SOTIO Biotech US and CTO of Unum Therapeutics, both autologous cell therapy companies. Before entering the cell therapy sector, Geoff Hodge co-founded Xcellerex, where he was the primary inventor of the XDR single-use bioreactor and head of the CDMO biomanufacturing services business, which helped the company grow to $50M in revenue before its acquisition by GE Healthcare.

In addition to his role on the Board of Cellular Origins, Geoff Hodge will remain part of the Scientific Advisory Board, where his extensive experience in developing biomanufacturing technology and proven commercial success has already helped to shape the Company’s strategic direction. As NED, Geoff will work closely alongside the Board and leadership team to accelerate growth and ensure continued development of the Company’s robotic platform for cost- and space-efficient manufacture of cell therapies, Constellation.

Geoff Hodge said: “Cellular Origins offers a transformative, industry-ready solution that addresses the challenges of manufacturing cell therapies at scale. I look forward to joining the Board and further deepening my involvement in the Company at this exciting time in its development and growth.”

For more information: https://cellularorigins.com/